TOP TEN perturbations for NM_000119 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000119
Selected probe(set): 210746_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000119 (210746_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

systemic onset JIA study 4 / juvenile enthesitis related arthritis study 2 (ERA)

Relative Expression (log2-ratio):5.738097
Number of Samples:3 / 3
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control juvenile enthesitis related arthritis study 2 (ERA)
Peripheral blood mononuclear cell (PBMC) samples from children with enthesitis related arthritis (ERA).

systemic onset JIA study 4 / oligoarticular JIA study 3

Relative Expression (log2-ratio):5.4339466
Number of Samples:3 / 12
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control oligoarticular JIA study 3
Peripheral blood mononuclear cell (PBMC) samples from children with persistent oligoarthritis (oligoarticular JIA).

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-5.431224
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

systemic onset JIA study 5 / oligoarticular JIA study 2

Relative Expression (log2-ratio):5.4074345
Number of Samples:3 / 12
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control oligoarticular JIA study 2
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of persistent oligoarticular juvenile idiopathic arthritis (JIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 5 / normal PBMC sample

Relative Expression (log2-ratio):5.143919
Number of Samples:3 / 27
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

systemic onset JIA study 4 / normal PBMC sample

Relative Expression (log2-ratio):5.134692
Number of Samples:3 / 27
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

systemic onset JIA study 5 / polyarticular JIA study 4 (RF negative)

Relative Expression (log2-ratio):5.0694265
Number of Samples:3 / 17
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control polyarticular JIA study 4 (RF negative)
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of polyarticular juvenile idiopathic arthritis, rheumatoid factor negative (polyJIA, RF neg.). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 4 / polyarticular JIA study 6

Relative Expression (log2-ratio):4.921051
Number of Samples:3 / 14
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control polyarticular JIA study 6
Peripheral blood mononuclear cell (PBMC) samples from children with rheumatoid factor negative polyarthritis (RF- polyarthritis/RF- polyarticular JIA).

systemic lupus erythematosus study 3 / normal blood sample

Relative Expression (log2-ratio):-4.4541492
Number of Samples:89 / 30
Experimental systemic lupus erythematosus study 3
Blood samples derived from patients with anti-ribonuclear protein-positive (anti-RNP+) systemic lupus erythematosus (SLE).
Control normal blood sample
Blood samples from healthy individuals.

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.398259
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.